Recent Updates
Recently added Catalysts

Upcoming Catalyst

Drug Pipeline Intelligence

Clinical Trial Results

Inside Trades

Options Data

News Section

Hedge Funds

Ownership Trends

Competitive Position

I-Mab Sponsored ADR

35 indications, side-by-side phase, drug & LoA

$4.63

-0.07 (-1.49%)

C 54Pipeline Score Fair Value Pharma · Clinical
Market Cap
366.66 M
EPS
-
P/E Ratio
-
Value Trade
7.01 M
-9.22 %
Week
28.61 %
1 Month
128.08 %
3 Month
426.14 %
6 Month
-88.63 %
5 Year
-68.61 %
All Time
Cash Data

  • Cash Position

    12.35 K

  • Monthly Burn

    12.35 K

  • Runway

    12,345 mo

Overview
Volume
1.51 M
52 Week Range
0.60 - 6.79
% held by Insiders
16.33 %
% held by Institutions
22.89 %
Enterprise Value
204.53 M
Total Shares
79.19 M
Short %
3.71 %
Float Shares
63.68 M
Company Description

locked

Upcoming Catalyst
Catalyst Drug/Treatment Stage Probability of Approval Description Drug Type Therapeutic Area Source
phase 2 data readout example
givastomig (bispecific Claudin 18.2 x 4-1BB antibody) Claudin 18.2-positive gastric cancers
Phase 2
—
Biologics
Oncology
givastomig (bispecific Claudin 18.2 x 4-1BB antibody) Claudin 18.2-positive gastric cancers
Phase 2
—
Biologics
Oncology
givastomig (bispecific Claudin 18.2 x 4-1BB antibody) Claudin 18.2-positive gastric cancers
Phase 2
—
Biologics
Oncology
Unlock Upcoming Catalyst data
Drug Pipeline Intelligence
C54
Pipeline Score
$841M
Pipeline Value
Fair Value
Valuation Signal
14
Drugs Scored
2.3x
rNPV / MCap
Top 83%
Micro Cap
(rank 155 of 905)
Percentile Rank
I-Mab Sponsored ADR carries a moderate pipeline score (54/100), with $4.4B risk-adjusted pipeline value, led by TJ004309 in Advanced Solid Tumor (Phase 1).
Showing 1 of 1 assets
DrugIndicationPhaseNCT IDPTRSrNPVStatusEnrollmentVelocityDesignCompletionML SignalLast Change
TJ004309
Small molecule		Ovarian CancerPhase 2NCT0500134710% $1.6B COMPLETED 25 - -Feb 8, 2023 -Dec 16, 2025
Unlock Drug Pipeline Intelligence
Clinical Trial Results
Drug Name Indications Phase Date Trial Results Summary Title Source
Givastomig
Metastatic gastric cancer,Gastroesophageal adenocarcinoma
Phase 1b
2025-06-26
Givastomig
Metastatic gastric cancer,Gastroesophageal adenocarcinoma
Phase 1b
2025-06-26
Givastomig
Metastatic gastric cancer,Gastroesophageal adenocarcinoma
Phase 1b
2025-06-26
Unlock Clinical Trial Results data
Inside Trades
TREND
CORPORATE INSIDERS BOUGHT SHARES WORTH 1.8M IN THE LAST 3 MONTHS
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Unlock Inside Trades data
Show Data
Hedge Funds
TREND
HEDGE FUNDS INCREASED HOLDINGS BY 200.0K SHARES IN THE LAST QUARTER
Shares Held
2040.00B1530.00B1020.00B510.00B0
Q3
2024
Q4
2024
Q1
2025
Q2
2025
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Fund Count
60%
Share Volume
25%
Conviction
15%
Hedge Funds invested in IMAB
HedgeFund Name
( 3 )
% of Portfolio Current MV
-
Shares Owned
-
Activity
Avg Price $0

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K
Unlock Hedge Funds table data
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
IMAB
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
IMAB
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
IMAB
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
Unlock Biotech Analyst Ratings data
IMAB Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
Unlock Price Target Trend
IMAB Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
ExpirationVolumeOpen InterestImplied Volatility CallsImplied Volatility Puts
CallsPutsPut-Call RatioCallsPutsPut-Call RatioIVOiWaIvVWaIvIVOiWaIvVWaIv
Unlock Option Chain Statistics data
Option Chain
CallsStrikePuts
Last PriceVolumeOpen InterestLast PriceVolumeOpen Interest
No data available
Unlock Option Chain data
Unlock Options Chart data
Open interest
0 600K 1.2M 1.8M Avg OI 1.00 M Open Interest
0 1 2 3 1.1 Put-Call Ratio
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
0 450K 900K 1.4M Avg OV 750.00 K Option Volume
0 1 2 3 0.95 Put-Call Ratio
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Latest I-Mab Sponsored ADR (IMAB) News & Alerts
-
Sunday, June 14, 2026
(%)
+ More

Demo Biotech Announces Positive Phase 3 Results

Competitive Position
How IMAB ranks across every disease it competes in
Indication Rank Phase Best DrugTop 3 Competitors Market $B LoA Position
Gout #4 of 4 PHASE 2 Plonmarlimab + Compound betamethasone
AMGN PLX NVO
$4.52B 0 CONTENDER
Esophageal Cancer #18 of 39 PHASE 2 Givastomig + Nivolumab + 5Fluorouracil + Leucovorin + Oxaliplatin + Capecitabine
AZN MRK ONC
$1.85B 0 FOLLOWER
Gastric Cancer #21 of 49 PHASE 2 Givastomig + Nivolumab + 5Fluorouracil + Leucovorin + Oxaliplatin + Capecitabine
AZN ONC JAZZ
$6.74B 0 FOLLOWER
Non-Small Cell Lung Cancer #47 of 88 PHASE 2 Uliledlimab + Sintilimab + Pemetrexed + Gemcitabine + Cisplatin Or Carboplatin
MRK AZN RVMD
$28.1B 0 FOLLOWER
Pancreatic Cancer #66 of 72 PHASE 1 TJ033721
RVMD RCUS AZN
$3.7B 0 FOLLOWER